E-submission
Search
- Page Path
- HOME > Search
Original Article
- Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
- Asmaa Gaber Abdou, Alaa Maraee, Hossam Yassien, Mona Sarhan
- J Pathol Transl Med. 2018;52(6):363-368. Published online October 23, 2018
- DOI: https://doi.org/10.4132/jptm.2018.09.18
- 8,673 View
- 189 Download
- 11 Web of Science
- 12 Crossref
-
Abstract
PDF - Background
Vitiligo is a chronic autoimmune disease in which the destruction of melanocytes causes white spots on the affected skin. Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK–signal transducer and activator of transcription pathway. The aim of the present study is to explore the possible role of JAK1 in the pathogenesis of vitiligo using immunohistochemical methods.
Methods
The current study was conducted in a sample of 39 patients who presented with vitiligo and 22 healthy individuals who were age and sex matched as a control group. We used immunohistochemistry to evaluate JAK1 status (intensity and distribution) and assess the percentage of residual melanocytes using human melanoma black 45 (HMB45).
Results
Intense and diffuse JAK1 expression was significantly more likely to indicate vitiliginous skin compared to normal skin (p < .001). Strong and diffuse JAK1 expression was associated with short disease duration, female sex, and lower percentage of melanocytes (detected by HMB45) (p < .05).
Conclusions
JAK1 may be involved in the pathogenesis of vitiligo, as indicated by intense and diffuse expression compared to control and association with lower percentage of melanocytes detected by HMB45 immunostaining. -
Citations
Citations to this article as recorded by
- Upadacitinib and its role in the treatment of vitiligo: A new possible therapeutic perspective
Jorge Magdaleno-Tapial, Pablo Hernández-Bel, Altea Esteve-Martínez, Rodrigo Peñuelas-Leal, Carolina Labrandero-Hoyos, José Luis Sánchez-Carazo, Amparo Pérez-Ferriols
JAAD Case Reports.2024; 46: 57. CrossRef - Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao, Yi Zhun Zhu
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef - Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection
Bo Xie, Yuqi Zhu, Yuqing Shen, Wen Xu, Xiuzu Song
Expert Opinion on Therapeutic Targets.2023; 27(3): 189. CrossRef - Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art
Federico Diotallevi, Helena Gioacchini, Edoardo De Simoni, Andrea Marani, Matteo Candelora, Matteo Paolinelli, Elisa Molinelli, Annamaria Offidani, Oriana Simonetti
International Journal of Molecular Sciences.2023; 24(5): 4910. CrossRef - Acid-responsive PEGylated branching PLGA nanoparticles integrated into dissolving microneedles enhance local treatment of arthritis
Hongmei Hu, Hang Ruan, Shuyao Ruan, Lixia Pei, Qian Jing, Tong Wu, Xiaolin Hou, Hao Xu, Youjie Wang, Nianping Feng, Yongtai Zhang
Chemical Engineering Journal.2022; 431: 134196. CrossRef - The skin delivery of tofacitinib citrate using transethosomes and hybridized ethosomes/nanostructured lipid carriers for vitiligo therapy: Dermatopharmacokinetics and in vivo assays
Heba Hesham, Mai Rady, Rania M. Hathout, Mohammad Abdel-Halim, Samar Mansour
International Journal of Pharmaceutics.2022; 629: 122387. CrossRef - Cutaneous JAK Expression in Vitiligo
Amira A. Abdel Motaleb, Yasmin M. Tawfik, Mohamed A. El-Mokhtar, Sherouk Elkady, Amira F. El-Gazzar, Suzan Kamel- ElSayed, Sara M. Awad
Journal of Cutaneous Medicine and Surgery.2021; 25(2): 157. CrossRef - Vitiligo: A focus on pathogenesis and its therapeutic implications
Christina Bergqvist, Khaled Ezzedine
The Journal of Dermatology.2021; 48(3): 252. CrossRef - Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Paul Smith, Wenqing Yao, Stacey Shepard, Maryanne Covington, Jim Lee, Jennifer Lofland, Ahmad Naim, Trupti Sheth, Bhavnish Parikh, Swamy Yeleswaram
Pharmaceutics.2021; 13(7): 1044. CrossRef - Vitiligo: A Review
Christina Bergqvist, Khaled Ezzedine
Dermatology.2020; 236(6): 571. CrossRef - Drug Repurposing Patent Applications January–March 2019
Hermann A.M. Mucke
ASSAY and Drug Development Technologies.2019; 17(5): 255. CrossRef - Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Michael D. Howell, Fiona I. Kuo, Paul A. Smith
Frontiers in Immunology.2019;[Epub] CrossRef
- Upadacitinib and its role in the treatment of vitiligo: A new possible therapeutic perspective
First
Prev
